| Medical treatment of glaucoma: present and future. | |
| | |
MedLine Citation:
|
PMID: 21534887 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In the last decades, the therapy of glaucoma has largely shifted from surgery to medical treatment thanks to the introduction of strongly effective formulations, that is, prostaglandin analogs and fixed combinations. This clinical scenario may dramatically change in the future thanks to the progresses in biochemistry, genetics and drug delivery technology. AREAS COVERED: This review covers the strategies currently used to achieve effective medical reduction of intraocular pressure in clinical practice; treatments that are currently been experimented in humans and that may be clinically available in the next few years; treatments at preclinical stages; and future goals of glaucoma treatment (gene therapy, ocular implants and neuroprotection). EXPERT OPINION: Apart from an adequate reduction of intraocular pressure, effective glaucoma treatments should guarantee other characteristics: good tolerability, low problems of adherence and, possibly, multiple ways of action. From this viewpoint, a crucial clinical role may be played by drugs remodeling the trabecular meshwork (i.e., ROCK inhibitors, metalloproteinases). Other strategies such as the use of ocular implants for drug delivery, neuroprotection or gene therapy could renew glaucoma management in the future, but need long-term rigorous verification of safety and efficacy. |
| | |
Authors:
|
Paolo Fogagnolo; Luca Rossetti |
Related Documents
:
|
12084497 - Once daily sustained release tablets of venlafaxine, a novel antidepressant. 14705187 - Release kinetics of catechins from chewing gum. 10613927 - Modeling of drug release from swellable polymers. 19604137 - Sustained release of diltiazem hydrochloride from chitosan micro-capsules. 20809897 - Pathway-specific, species, and sub-type counterscreening for better gpcr hits in high t... 20940707 - Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of panc... |
Publication Detail:
|
Type: Journal Article; Review Date: 2011-05-03 |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 20 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-06-13 Completed Date: 2012-05-07 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 947-59 Citation Subset: IM |
Affiliation:
|
G. B. Bietti Foundation - IRCC, Rome, Italy. fogagnolopaolo@googlemail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / administration & dosage, metabolism Glaucoma / drug therapy*, metabolism, surgery* Humans Intraocular Pressure / drug effects, physiology Neuroprotective Agents / administration & dosage, metabolism Ophthalmic Solutions / administration & dosage, metabolism Predictive Value of Tests Prostaglandins / administration & dosage, metabolism Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Neuroprotective Agents; 0/Ophthalmic Solutions; 0/Prostaglandins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antiretroviral use during pregnancy for treatment or prophylaxis.
Next Document: Volatile and lipid analyses by gas chromatography/mass spectrometry and nutraceutical potential of e...